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Systematic reviews comparing the effectiveness of strategies to prevent, detect, and treat chronic kidney disease
are needed to inform patient care. We engaged stakeholders in the chronic kidney disease community to prioritize
topics for future comparative effectiveness research systematic reviews. We developed a preliminary list of
suggested topics and stakeholders refined and ranked topics based on their importance. Among 46 topics
identified, stakeholders nominated 18 as ‘high’ priority. Most pertained to strategies to slow disease progression,
including: (a) treat proteinuria, (b) improve access to care, (c) treat hypertension, (d) use health information
technology, and (e) implement dietary strategies. Most (15 of 18) topics had been previously studied with two or
more randomized controlled trials, indicating feasibility of rigorous systematic reviews. Chronic kidney disease topics
rated by stakeholders as ‘high priority’ are varied in scope and may lead to quality systematic reviews impacting
practice and policy.
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Evidence to inform the optimal care of patients at risk of
chronic kidney disease (CKD) incidence or progression
is greatly needed. Patients, clinicians, and policy makers
[1-7] want evidence about effective strategies to: (1) pre-
vent incident CKD, (2) improve the accuracy and timely
detection of CKD, (3) treat CKD effectively to limit pro-
gression to end stage renal disease (ESRD), and (4) de-
crease morbidity from CKD-related comorbid illnesses.
Comparative effectiveness research (CER) compares “the
benefits and harms of various interventions and strat-
egies for preventing, diagnosing, treating and monitoring
health conditions in real-world settings.” [8] The Ameri-
can Recovery and Reinvestment Act (ARRA) of 2009
provided $1.1 billion for CER which was divided and dis-
bursed to the National Institutes of Health, the Agency* Correspondence: dcrews1@jhmi.edu
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reproduction in any medium, provided the orfor Healthcare Research and Quality and the Office of
the Secretary of Health and Human Services [9]. The In-
stitute of Medicine was tasked to recommend national
priorities for research questions to be addressed by CER
and supported by ARRA funds. Among the Institute’s
list of 100 initial priority topics, two addressed kidney
disease [8].
A core research method of CER is systematic review
and synthesis of existing literature, but this has not been
widely employed to study CKD care. Findings from sys-
tematic reviews can help decision-makers draw conclu-
sions about effective care strategies employed among
heterogeneous populations and clinical settings. System-
atic reviews also help to identify gaps in the existing evi-
dence that need to be addressed by future primary
research studies [10].
CER studies may be distinguished from other types of
clinical research by their explicit goal of being highly re-
sponsive to priorities of community stakeholders (per-
sons or groups who have a vested interest in a clinical
decision and the evidence that supports that decision)
who will use study findings to support their decisions
about care [11]. Research funding agencies increasinglytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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an important initial step in designing CER studies.
[11,12]. To date, there has been little effort to identify
priorities for CER among stakeholders in the CKD com-
munity and to share this with the CKD community at
large. We engaged stakeholders within the CKD com-
munity to identify and prioritize topics for future CER
systematic reviews and to help set an agenda for future
primary CER studies of CKD care.Methods
General approach
The Johns Hopkins University Evidence-Based Practice
Center (EPC) assembled our team under a contract from
the Agency for Healthcare Research and Quality
(AHRQ) of the Department of Health and Human Ser-
vices. Our primary goal was to use the input of commu-
nity stakeholders to identify topics for systematic
reviews of primary literature comparing the effectiveness
of strategies to prevent, detect, and treat CKD or its
complications. We also sought to identify topics for fu-
ture CER studies of CKD care where the performance of
systematic reviews might not be currently feasible due to
lack of sufficient primary literature to review. Our team
had clinical expertise in pediatric nephrology, adult
nephrology, and general internal medicine, and research
expertise in CER, clinical epidemiology and prevention
of CKD, clinician practice patterns in the care of patients
with CKD, health disparities, and systematic review
methodology.
We established a preliminary protocol for identifying
and prioritizing topics, which we later revised with input
from the stakeholders. The protocol consisted of three
main activities: (1) identifying and categorizing potential
topics of interest to the CKD community for systematic
review and primary CER studies, (2) asking stakeholders
to rank topics that would be of greatest interest to the
CKD community, and (3) exploring the feasibility ofDe eloped• v  











Figure 1 Chronic Kidney Disease Comparative Effectiveness Researchperforming CER systematic reviews on these high prior-
ity topics (Figure 1).
Preliminary categorization and identification of topics for
CER studies
From the outset, our team acknowledged the breadth of
topics potentially relevant to the care of patients with
CKD, ranging from studies of strategies to prevent CKD,
to studies of strategies to prevent morbidity and mortal-
ity among patients with end stage renal disease (ESRD).
We decided a priori to restrict our efforts to identifying
priorities for CER reviews relevant to the care of patients
with CKD stages I-IV because of time limitations (the
process was funded to occur in less than 1 year) and dif-
fering considerations relevant to the care of patients
with early or progressive CKD versus the care of patients
with ESRD. To categorize the topics, we developed a
preliminary ‘map’ reflecting broad domains of CKD care
(prevention, detection, progression and complications)
prior to engaging stakeholders. Within each broad do-
main, we developed a preliminary list of potential topics
through an iterative process informed by our review of
recent clinical practice guidelines [12-14] and perspec-
tives pieces published by CKD thought leaders. We iden-
tified topics without regard to whether they were the
subject of ongoing reviews. For many of the topics, we
also identified numerous subtopics that could be of
interest to the CKD community.
Selection of CKD community stakeholder representatives
We sought to identify individuals representing varied
stakeholder perspectives relevant to the performance of
CER in CKD care. Many of the individuals we identified
were employed or had active memberships in organiza-
tions representing relevant decision-makers in the CKD
community and/or had clinical expertise relevant to the
care of patients with CKD. (Table 1) Because we
hypothesized government agencies such as the National
Institutes of Health (NIH) might use the results ofAssessed•  
feasibility of CER 
rs from 
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reviews on topic 





(CER) Topic Identification Process.
Table 1 Organization Types and Clinical Expertise
Represented by Expert Stakeholders*
Organization Types Clinical Expertise
• Patient Advocacy Groups (2) • Primary Care (Family Practice
and Internal Medicine)
• Health Professional Societies (2) • Adult Nephrology
• Private Healthcare Insurer (1) • Pediatric Nephrology
• Governmental Healthcare Insurer (2) • Endocrinology
• National Institutes of Health (2)
Not representing an organization (2)
* Stakeholders included 4 federal employees and 7 not affiliated with a
governmental agency.
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engaged program officers overseeing clinical studies for
their input.
Community Stakeholder Engagement
We asked stakeholders to provide input on our approach
to identifying potential CER research topics and to rank the
importance of topics. We engaged them via two conference
calls and several electronic and mailed communications.
We reviewed definitions of CER as presented by
AHRQ, the Institute of Medicine and the Federal Coord-
inating Council for Comparative Effectiveness Research
[8] with stakeholders. We then presented the prelimin-
ary map of domains for CER topics to stakeholders. The
map reflected four areas of potential interest to the CKD
community: (1) prevention of CKD, (2) detection of
CKD, (3) progression of CKD, and (4) complications of
CKD. We also presented stakeholders with a preliminary
list of 30 potential topics for CER research. We solicited
stakeholders’ feedback regarding: (1) the relevance and
appropriateness of our preliminary conceptual map, and
(2) the relevance and comprehensiveness of the prelim-
inary list of topics we proposed. We asked stakeholders
to add to our preliminary list of topics.
We also asked stakeholders to establish a set of criteria
for ranking topics. We proposed four criteria which they
might consider, including (1) the burden of the topic to
patients with CKD or patients at risk of developing CKD
(including consideration of whether that topic was of
particular relevance to priority subpopulations such as
patients with diabetes, pediatric patients, racial/ethnic
minorities or other vulnerable populations); (2) the ex-
tent to which there is uncertainty regarding optimal
approaches to the topic; (3) the extent to which a sys-
tematic review with definitive findings could impact
decision-making by patients, clinicians, or policy makers,
and (4) the feasibility of performing a systematic review
(i.e., adequacy of literature facilitating a rigorous review
and the absence of recent previous systematic reviews).
However, stakeholders expressed concern about theavailability of literature to perform systematic reviews in
several areas, and therefore decided to prioritize topics
without regard to feasibility. Our team subsequently car-
ried out a feasibility assessment of the stakeholder-
prioritized topics.
Stakeholders revised our preliminary list of CER topics
by refining the proposed topics and adding additional
topics. Stakeholders then each independently ranked
their 10 highest priority topics for CER studies (10 for
highest, 1 for lowest). We calculated a summary score
reflecting each topic’s overall standing among stake-
holders (Additional file 1: Appendix A). We allowed ties
for overall rankings and shared the final ranked list of
topics with stakeholders to learn whether the composite
rankings reflected the consensus of the entire group. We
then asked them to identify topics they thought should
be recommended for systematic reviews by AHRQ’s Evi-
dence Based Practice Centers.
Assessment of CER systematic review feasibility
We conducted preliminary literature searches to esti-
mate the feasibility of performing CER systematic
reviews on topics ranked highly by stakeholders. We
searched publication titles in PubMed to identify rele-
vant studies using terms sufficient to identify a reason-
able core of the studies on a topic. We did not intend
for these searches to be as exhaustive as would be
required for formal systematic reviews. We assessed the
availability of published systematic reviews/meta-ana-
lyses (within the past 5 years), randomized controlled
trials (RCTs), and observational studies (if no systematic
reviews/meta-analyses or RCTs were identified on a
topic) for each top tier topic area. For RCTs and obser-
vational studies, we reviewed up to 300 of the most re-
cent PubMed records for each topic. We noted whether
studies pertained to specific priority populations and
whether trial interventions were pharmacological or
non-pharmacological. Search protocol and search terms
are contained in Additional file 2: Appendix B.Findings
Final categorization and list of potential topics for CER
studies
Stakeholders agreed that the four proposed domains for
categorizing topics for CER appropriately reflected the
range of potential CER topics about CKD care, and
added 16 additional topics to our preliminary list of 30
topics. Table 2 lists the 46 topics (grouped by domain, in
no particular order) and example CER questions. The
example questions are intended to illustrate ways in
which CER topics could be framed, but they are not
intended to limit the range of CER questions which
could be asked regarding CER topic areas.
Table 2 List of topics considered by stakeholders for Comparative Effectiveness Systematic Reviews
Topic Example Question*
Prevention
1** Patient knowledge/education What is the effectiveness of strategies to improve patient knowledge or awareness of CKD and
CKD risk factors on decreasing CKD incidence?
2 Hypertension What is the comparative effectiveness of hypertension management (pharmacologic and
non-pharmacologic) on CKD incidence?
3 Diabetes control and prevention What is the comparative effectiveness of diabetes management (pharmacologic and
non-pharmacologic) on CKD incidence?
4 Patient Safety What is the effectiveness of patient safety interventions on decreasing the incidence of
acute kidney injury/CKD (i.e. exposure to contrast/dyes, nephrotoxins [NSAIDS])?
5 Smoking cessation and prevention What is the comparative effectiveness of smoking cessation strategies on CKD incidence?
6 Lipid management What is the comparative effectiveness of lipid management strategies on CKD incidence?
7 Vitamin D What is the effectiveness of normalizing Vitamin D levels among deficient or insufficient patients
in preventing CKD?
8 Obesity/Weight Management What is the effectiveness of obesity/weight management interventions in decreasing CKD incidence?
Detection
9 Screening benefits and harms What are the benefits and harms of screening versus usual detection of CKD?
10 Screening frequency What is the optimal screening frequency in populations at high-risk of CKD incidence?
11 Classification Which estimations of GFR accurately classify people as having CKD? Including the correct stage?
12 Automated estimated GFR reporting Does automated estimated GFR reporting lead to changes in clinical management and outcomes
(drugs/referral)?
Progression
13 Health Information Technology What is the effectiveness of computer decision support for CKD management
(including medication dosing) in slowing CKD progression?
14 Hyperuricemia Is treatment of hyperuricemia an effective strategy for slowing CKD progression?
15 Inflammation What is the comparative effectiveness of strategies to reduce markers of inflammation
(i.e. C-reactive protein) in slowing CKD progression?
16 Provider awareness and
guideline adherence
What is the effectiveness of strategies to improve provider awareness and adherence to guidelines
on improving outcomes (progression) for patients with CKD?
17 Collaboration strategies What is the effectiveness of strategies to increase collaboration in care (i.e. primary care/nephrology
and team based approaches) of CKD patients in slowing CKD progression?
18 Diabetes management What is the effectiveness and comparative effectiveness of diabetes management strategies
(i.e. pharmacologic and behavioral strategies, therapeutic targets) in slowing CKD progression?
19 Vitamin D Is vitamin D therapy effective in slowing CKD progression?
20 Hypertension What is the comparative effectiveness of strategies to treat hypertension (i.e. target, medication
combinations, behavioral strategies, lifestyle interventions) in slowing CKD progression?
21 Proteinuria Is targeted therapy to reduce proteinuria (ie. optimal proteinuria target, specific therapies) effective
in slowing CKD progression?
22 Patient safety What is the effectiveness of patient safety interventions on slowing CKD progression?
23 Access to care Is improved access to care (including primary or nephrology care) an effective mechanism for
slowing CKD progression?
24 Cardiovascular disease Are interventions to manage heart failure and coronary artery disease effective in slowing
CKD progression?
25 Dietary strategies What is the effectiveness or comparative effectiveness of dietary strategies in slowing
CKD progression?
26 Congenital urologic disease What is the effectiveness and comparative effectiveness of strategies to treat congenital urologic
disease in slowing CKD progression?
27 Acute kidney injury What is the comparative effectiveness of management strategies of AKI in slowing CKD progression?
28 Preparation for renal replacement therapy What is the comparative of strategies (e.g., education, shared decision-making, fistula placement) to
prepare patients for renal replacement therapy?
29 Metabolic acidosis Is treatment of metabolic acidosis an effective strategy for slowing CKD progression?
30 Anemia Is treatment of anemia an effective strategy for slowing CKD progression?
31 Dyslipidemia Is treatment of dyslipidemia an effective strategy in slowing CKD progression?
32 Renovascular disease Are renovascular interventions effective in slowing CKD progression?
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Table 2 List of topics considered by stakeholders for Comparative Effectiveness Systematic Reviews (Continued)
Complications
33 Cardiovascular Disease (CVD) What is the effectiveness or comparative effectiveness of strategies to prevent or treat CVD among
patients with CKD?
34 Patient Educational Interventions What is the effectiveness of patient educational interventions in reducing CKD complications?
35 Bone/Mineral Disease What is the effectiveness or comparative effectiveness of strategies to screen, evaluate and treat
bone/mineral disease among patients with CKD?
36 Hypertension What is the effectiveness or comparative effectiveness of blood pressure management strategies
among patients with CKD?
37 Inflammation What is the comparative effectiveness of strategies to reduce markers of inflammation (i.e., CRP) in
slowing CKD progression?
38 Nutrition/Growth What is the effectiveness of strategies to prevent, evaluate, and treat poor growth and malnutrition
among patients with CKD?
39 Health Information Technology What is the effectiveness of computer decision support for CKD management in reducing complications?
40 Collaborative Care What is the effectiveness of strategies to increase collaboration (i.e., primary care/nephrology and
team based approaches) in care of CKD for reducing CKD complications?
41 Patient Safety What is the effectiveness of patient safety interventions in reducing complications among CKD patients?
42 Patient Reported Outcomes What is the effectiveness of interventions to improve patient reported CKD complications
(i.e. symptoms, sexual dysfunction, quality of life)?
43 Anemia What is the effectiveness or comparative effectiveness of strategies to screen, evaluate,
and treat anemia in patients with CKD?
44 Acute Kidney Injury What is the effectiveness or comparative effectiveness of strategies to prevent or treat acute kidney
injury among patients with CKD?
45 Functional status What is the effectiveness of strategies to evaluate and improve functional status
(i.e. rehabilitation interventions) among patients with CKD?
46 Fluid management What is the effectiveness or comparative effectiveness of treatment strategies for volume overload
among patients with CKD?
*Example questions are intended to illustrate ways in which CER topics can be framed, but are not intended to reflect questions themselves.
**Topics are grouped by domain, in no particular order.
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After stakeholders collectively reviewed the summary
rankings, they agreed that topics with a global rank of
12 or better should be considered ‘high priority’ for fu-
ture funded CER reviews. Because of ties, this cutoff
resulted in 18 topics being considered ‘high priority.’
There was diversity in the opinions of the stakeholders
regarding the appropriateness of topic areas for CER sys-
tematic reviews, with some stakeholders expressing con-
cern regarding the likely paucity of evidence to compare
existing strategies of care in certain topic areas. How-
ever, in general, stakeholders’ rankings were consistent,
reflecting overall consensus regarding the appropriate-
ness of topics for which CER systematic reviews would
be of greatest interest to the CKD community. One
anomaly was that one stakeholder’s top ranked topic, ‘in-
flammation in the progression of CKD’, was not ranked
at all by any other stakeholder. Yet that top ranking by a
single stakeholder was sufficient for it to be included
among the top tier of topics. (Table 3) Half (n = 9) of top
tier topics focused on strategies to slow or stop progres-
sion of CKD, while fewer top tier topics focused on pre-
vention of CKD (n = 6), detection of CKD (n = 2), and
complications of CKD (n = 1). Two topics emerged
among the top tier priorities in more than one area ofthe conceptual map, patient safety (in prevention and
progression areas) and hypertension (in prevention and
progression areas).Feasibility of performing CER systematic reviews on
priority topics
Our preliminary assessment suggested some systematic
reviews could be feasibly performed, with some topics
having sufficient trial data and others having only obser-
vational data. (Table 3) Some of the priority topics iden-
tified, including ‘screening for CKD’ and ‘management of
hypertension and lipid levels’, were previously reviewed
in the AHRQ-funded evidence report Screening for and
Management of Chronic Kidney Disease Stages 1-3 [15].Discussion
This project is one of the first attempts to systematically
assess priorities for CER studies among stakeholders in
the CKD community. Stakeholders’ high priority rank-
ings reflect topics posing significant burden to patients
with CKD or at risk of CKD, and aspects of CKD care
for which there is significant uncertainty regarding ef-
fectiveness. High rankings also reflect stakeholders’
views that high-quality systematic reviews could help
Table 3 Topics receiving highest priority rankings for funded comparative Effectiveness Systematic Reviews in CKD
Topic CKD Area Rank* Feasibility
Systematic reviews **Randomized controlled trials
Pharmacologic Behavioral †Priority population
Proteinuria Progression 1 9 >100 20 0
Access to care Progression 2 1 2 2 2
Hypertension Progression 2 11 68 3 37
Screening benefits and harms Detection 3 1 0 0 0
Hypertension control Prevention 4 0 1 0 0
Patient knowledge/education Prevention 5 0 0 3 3
Diabetes control and prevention Prevention 6 2 18 3 23
Cardiovascular Disease Complications 7 3 40 0 5
Patient safety Progression 7 5 64 2 4
Health Information Technology Progression 8 0 5 1 0
Patient Safety Prevention 9 24 29 0 3
Vitamin D Prevention 10 0 7 0 7
Classification Detection 11 4 0 0 {10
Obesity/Weight Management Prevention 12 0 0 5 1
Dietary strategies Progression 12 11 0 13 3
Inflammation Progression 12 2 21 0 5
Collaboration strategies Progression 12 0 0 2 1
Metabolic acidosis Progression 12 0 4 0 0
* Topics with the same priority rank were tied in the overall score they received across all of the stakeholders. Rankings were based on responses received from 9
stakeholders.
**Randomized controlled trial categories are not mutually exclusive.
†Priority populations include: patients with diabetes, pediatric population, racial/ethnic minorities,
and other vulnerable populations.
‡Ten observational studies examined priority populations (27 total). No randomized control trials.
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through this process may not include all topics that war-
rant CER systematic reviews or primary CER studies,
this process may provide a preliminary road map for
researchers seeking to perform CER studies relevant to
the CKD community.
Many topics receiving a ‘high priority’ designation by
stakeholders focused on studying the effectiveness of
strategies to prevent CKD incidence and to slow CKD
progression. Some highly ranked topic areas, such as ‘pa-
tient safety’, were reflected in multiple domains of the
conceptual map. Because they are viewed as relevant to
several aspects of CKD care and prevention, rigorous
CER reviews on these topics could have high impact on
patient care and clinical outcomes. Other topics, such as
studies evaluating the comparative effectiveness of
health information technology and the study of collab-
orative care strategies (both ranked as ‘top tier’ by our
stakeholders), represent novel areas of inquiry. We iden-
tified few studies of these topics during our feasibility as-
sessment, potentially reflecting a potential need for
primary CER studies in these areas.
There are several caveats to our engagement of stake-
holders for their input. First, the group of stakeholderswas relatively small. Thus, individual stakeholders’ rank-
ings could substantially affect topics’ overall final rankings
and might not reflect fully the range of opinions that
might be present among the entire CKD community. In-
deed, some stakeholders did express concerns regarding
the appropriateness of some topics for CER reviews, given
a paucity of evidence to address these topics. Second, the
composition of our stakeholder group and the manner in
which we contacted stakeholders for participation in this
exercise could also affect our findings. Third, while our
stakeholder group included representatives from two pa-
tient advocacy organizations, we did not include actual
patients with CKD. Methods for selecting patients with
appropriate levels of expertise (i.e., medical knowledge,
awareness of issues affecting patients with CKD relevant
to comparative effectiveness research) for this type of sci-
entific effort are not yet well defined. Fourth, stakeholders’
input may also have been further enriched by our inclu-
sion of non-physician medical professionals such as
nurses, social workers and dietitians. Future efforts to
identify topics for CER reviews should consider broaden-
ing stakeholder representation to include patients and
non-physician medical professionals. Fifth, some stake-
holders did submit additional comments in with their
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ings. However, because all stakeholders did not comment
to the same extent, we did not formally analyze these
comments. Finally, as this was one of the first funded
efforts to identify priorities for CER systematic reviews
in CKD, diversity in stakeholders’ opinions could also
reflect their varying interpretations of the ultimate goal
of activities such as this.
Other characteristics of our approach could also have
influenced our findings. For instance, we developed the
map and topic lists via iterative discussions prior to
obtaining stakeholders’ input, and without regard to on-
going systematic reviews, which may have influenced the
range of the final list of topics that the stakeholders
ranked. Future projects of this kind may benefit from
assessing and comparing independently determined pri-
orities of different groups of stakeholders, including pol-
icy makers, funding agencies, clinicians and patients.
Also, while our preliminary findings suggest several
topics may have enough evidence to make CER system-
atic reviews feasible, several factors determine whether a
systematic review will add value to inform medical
decision-makers, including the number and quality of
studies available to review, how definitively identified
studies answer the question of interest, and how answers
to questions will reduce uncertainty or add to the
current knowledge and ultimately impact care. These
factors should all be considered prior to undertaking
CER systematic reviews.
In conclusion, we systematically identified priorities
for CER research relevant to the care of patients with
Stages I-IV CKD among stakeholders in the CKD com-
munity. Future efforts such as ours might benefit from
identification of an even more broadly defined group of
stakeholders (e.g., patients and non-physician CKD
health professionals), further refinement of protocols
for engaging stakeholders throughout the topic identifi-
cation process, and development of strategies for iden-
tifying areas in need of both CER systematic reviews as
well as primary CER studies. Findings from this project
may be a useful guide for researchers and research fun-
ders seeking to address CER questions highly relevant
to improving clinical care and outcomes of patients
with CKD.Additional files
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